Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies

Acta Obstetricia et Gynecologica Scandinavica

Volumn 93, Issue 1, 2014, Pages 6-19

  Svahn, Malene F ^a   Faber, Mette T ^a   Christensen, Jane ^a   Norrild, Bodil ^b   Kjaer, Susanne K ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Epidemiology; human papillomavirus; meta analysis; meta regression; ovarian cancer; prevalence; review

Indexed keywords

ASIA; CANCER TISSUE; EASTERN EUROPE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; META ANALYSIS (TOPIC); NORTH AMERICA; OBSERVATIONAL STUDY; OVARY CARCINOMA; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VIRUS DETECTION; WART VIRUS; WESTERN EUROPE;

EPIDEMIOLOGY; HUMAN PAPILLOMAVIRUS; META-ANALYSIS; META-REGRESSION; OVARIAN CANCER; PREVALENCE; REVIEW;

FEMALE; HUMANS; OVARIAN NEOPLASMS; OVARY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84890559829     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12254     Document Type: Review

References (80)

1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW,. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008; 44: 1345-89.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
3. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104: 2807-16.
4. Granstrom C, Sundquist J, Hemminki K,. Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer. 2008; 98: 199-205.
5. Riman T, Nilsson S, Persson IR,. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand. 2004; 83: 783-95.
6. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1160-6.
7. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000; 11: 111-7.
8. Hussain SP, Harris CC,. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121: 2373-80.
9. Ness RB, Cottreau C,. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999; 91: 1459-67.
10. Ness RB, Goodman MT, Shen C, Brunham RC,. Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer. J Infect Dis. 2003; 187: 1147-52.
11. Idahl A, Lundin E, Elgh F, Jurstrand M, Moller JK, Marklund I, et al. Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol. 2010; 202: 71-6.
12. Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K,. Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis. 2012; 31: 2311-7.
13. Kaufman RH, Bornstein J, Gordon AN, Adam E, Kaplan AL, Adler-Storthz K,. Detection of human papillomavirus DNA in advanced epithelial ovarian carcinoma. Gynecol Oncol. 1987; 27: 340-9.
14. World Health Organization International Agency for Research on Cancer. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90: 1-636.
15. Yang HJ, Liu VW, Tsang PC, Yip AM, Ng TY, Cheung AN, et al. Comparison of human papillomavirus DNA levels in gynecological cancers: implication for cancer development. Tumour Biol. 2003; 24: 310-6.
16. Chan PJ, Seraj IM, Kalugdan TH, King A,. Evidence for ease of transmission of human papillomavirus DNA from sperm to cells of the uterus and embryo. J Assist Reprod Genet. 1996; 13: 516-9.
17. Ostrow RS, Zachow KR, Niimura M, Okagaki T, Muller S, Bender M, et al. Detection of papillomavirus DNA in human semen. Science. 1986; 231: 731-3.
18. Flores-Sanchez I, Gutierrez-Salinas J, Enriquez-Alvarado E, Hernandez-Rodriguez S, Ramos-Barragan C, Salamanca-Ceciliano A, et al. Detection of human papillomavirus types 16 and 18 in semen samples from patients in an assisted reproduction program [in Spanish]. Ginecol Obstet Mex. 2010; 78: 645-51.
19. Kaspersen MD, Larsen PB, Ingerslev HJ, Fedder J, Petersen GB, Bonde J, et al. Identification of multiple HPV types on spermatozoa from human sperm donors. PLoS One. 2011; 6: e18095.
20. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM,. Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health. 2011; 48: 540-52.
21. Lai CH, Hsueh S, Lin CY, Huang MY, You GB, Chang HC, et al. Human papillomavirus in benign and malignant ovarian and endometrial tissues. Int J Gynecol Pathol. 1992; 11: 210-5.
22. Fathalla MF,. Incessant ovulation-a factor in ovarian neoplasia? Lancet. 1971; 2: 163.
23. Atalay F, Taskiran C, Taner MZ, Pak I, Or M, Tuncer S,. Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma. J Obstet Gynaecol Res. 2007; 33: 823-8.
24. Ip SM, Wong LC, Xu CM, Cheung AN, Tsang PC, Ngan HY,. Detection of human papillomavirus DNA in malignant lesions from Chinese women with carcinomas of the upper genital tract. Gynecol Oncol. 2002; 87: 104-11.
25. Giordano G, D'Adda T, Gnetti L, Froio E, Merisio C, Melpignano M,. Role of human papillomavirus in the development of epithelial ovarian neoplasms in Italian women. J Obstet Gynaecol Res. 2008; 34: 210-7.
26. Erickson BK, Conner MG, Landen CN Jr,. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013; doi: 10.1016/j.ajog.2013.04.019 [Epub ahead of print].
27. Rosa MI, Silva GD, de Azedo Simoes PW, Souza MV, Panatto AP, Simon CS, et al. The prevalence of human papillomavirus in ovarian cancer: a systematic review. Int J Gynecol Cancer. 2013; 23: 437-41.
28. Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing HP, et al. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer. 2002; 95: 2571-6.
29. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc. 2000; 283: 2008-12.
30. Clopper CJ, Pearson ES,. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26: 404-13.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. Br Med J. 2003; 327: 557-60.
32. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR,. Meta-regression. In: Introduction to meta-analysis, 1st edn. Chichester: Wiley, 2009. pp. 187-203.
33. Egger M, Davey SG, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997; 315: 629-34.
34. Lai CH, Wang CY, Lin CY, Pao CC,. Detection of human papillomavirus RNA in ovarian and endometrial carcinomas by reverse transcription/polymerase chain reaction. Gynecol Obstet Invest. 1994; 38: 276-80.
35. Wu QJ, Guo M, Lu ZM, Li T, Qiao HZ, Ke Y,. Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer. 2003; 89: 672-5.
36. Zimna K, Poreba E, Kedzia W, Gozdzicka-Jozefiak A, Kedzia H,. Human papillomavirus (HPV) in upper genital tract carcinomas of women. Eur J Gynaecol Oncol. 1997; 18: 415-7.
37. Kuscu E, Ozdemir BH, Erkanli S, Haberal A,. HPV and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2005; 26: 642-5.
38. Bilyk OO, Pande NT, Buchynska LG,. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas. Exp Oncol. 2011; 33: 150-6.
39. Malisic E, Jankovic R, Jakovljevic K,. Detection and genotyping of human papillomaviruses and their role in the development of ovarian carcinomas. Arch Gynecol Obstet. 2012; 286: 723-8.
40. Leake JF, Woodruff JD, Searle C, Daniel R, Shah KV, Currie JL,. Human papillomavirus and epithelial ovarian neoplasia. Gynecol Oncol. 1989; 34: 268-73.
41. Beckmann AM, Sherman KJ, Saran L, Weiss NS,. Genital-type human papillomavirus infection is not associated with surface epithelial ovarian carcinoma. Gynecol Oncol. 1991; 43: 247-51.
42. Trottier AM, Provencher D, Mes-Masson AM, Vauclair R, Coutlee F,. Absence of human papillomavirus sequences in ovarian pathologies. J Clin Microbiol. 1995; 33: 1011-3.
43. Chen TR, Chan PJ, Seraj IM, King A,. Absence of human papillomavirus E6-E7 transforming genes from HPV 16 and 18 in malignant ovarian carcinoma. Gynecol Oncol. 1999; 72: 180-2.
44. Quirk JT, Kupinski JM, DiCioccio RA,. Analysis of ovarian tumors for the presence of human papillomavirus DNA. J Obstet Gynaecol Res. 2006; 32: 202-5.
45. de Villiers EM, Schneider A, Gross G, zur Hausen H,. Analysis of benign and malignant urogenital tumors for human papillomavirus infection by labelling cellular DNA. Med Microbiol Immunol. 1986; 174: 281-6.
46. Runnebaum IB, Maier S, Tong XW, Rosenthal HE, Mobus VJ, Kieback DG, et al. Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients. Cancer Epidemiol Biomarkers Prev. 1995; 4: 573-5.
47. Anttila M, Syrjanen S, Ji H, Saarikoski S, Syrjanen K,. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol. 1999; 72: 337-41.
48. Wentzensen N, du BA, Kommoss S, Pfisterer J, von Knebel DM, Schmidt D, et al. No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group. Int J Gynecol Pathol. 2008; 27: 18-23.
49. Duggan MA, Rowlands C, Kneafsey PD, Nation JG, Stuart GC,. Uterine atypical polypoid adenomyoma and ovarian endometrioid carcinoma: metastatic disease or dual primaries? Int J Gynecol Pathol. 1995; 14: 81-6.
50. Manolitsas TP, Lanham SA, Hitchcock A, Watson RH,. Synchronous ovarian and cervical squamous intraepithelial neoplasia: an analysis of HPV status. Gynecol Oncol. 1998; 70: 428-31.
51. Verguts J, Amant F, Moerman P, Vergote I,. HPV induced ovarian squamous cell carcinoma: case report and review of the literature. Arch Gynecol Obstet. 2007; 276: 285-9.
52. Mai KT, Yazdi HM, Bertrand MA, LeSaux N, Cathcart LL,. Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Am J Surg Pathol. 1996; 20: 767-72.
53. Giordano G, Azzoni C, D'Adda T, Rocco A, Gnetti L, Froio E, et al. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Pathol Res Pract. 2008; 204: 163-74.
54. Malisic E, Jankovic R, Jakovljevic K, Radulovic S,. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas. J BUON. 2011; 16: 701-7.
55. Hisada M, van den Berg BJ, Strickler HD, Christianson RE, Wright WE, Waters DJ, et al. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control. 2001; 12: 335-41.
56. Konidaris S, Kouskouni EE, Panoskaltsis T, Kreatsas G, Patsouris ES, Sarivalassis A, et al. Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women. Health Care Women Int. 2007; 28: 182-91.
57. Ishiwata I, Ishiwata C, Soma M, Akagi H, Hiyama H, Nakaguchi T, et al. Presence of human papillomavirus genome in human tumor cell lines and cultured cells. Anal Quant Cytol Histol. 1991; 13: 363-70.
58. Anwar K, Nakakuki K, Imai H, Shiraishi T, Inuzuka M,. Infection of human papillomavirus (HPV) and p53 over-expression in human female genital tract carcinoma. J Pak Med Assoc. 1996; 46: 220-4.
59. McLellan R, Buscema J, Guerrero E, Shah KV, Woodruff JD, Currie JL,. Investigation of ovarian neoplasia of low malignant potential for human papillomavirus. Gynecol Oncol. 1990; 38: 383-5.
60. Kaufman RH, Adam E, Adler-Storthz K,. Absence of human papillomavirus (HPV) DNA sequences in epithelial ovarian carcinoma. Gynecol Oncol. 1990; 37: 148.
61. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105: 175-201.
62. Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM, et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997; 89: 796-802.
63. Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett. 2000; 156: 159-65.
64. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol. 2000; 81: 2959-68.
65. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 2001; 93: 1325-30.
66. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst. 2001; 93: 315-8.
67. Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol. 1993; 67: 6413-23.
68. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, et al. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol. 1993; 67: 6424-31.
69. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA,. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995; 69: 7743-53.
70. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997; 71: 2463-72.
71. Stewart AC, Eriksson AM, Manos MM, Munoz N, Bosch FX, Peto J, et al. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol. 1996; 70: 3127-36.
72. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998; 393: 229-34.
73. Hildesheim A, Wang SS,. Host and viral genetics and risk of cervical cancer: a review. Virus Res. 2002; 89: 229-40.
74. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y,. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res. 1998; 58: 4585-6.
75. Ngan HY, Liu VW, Liu SS,. Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br J Cancer. 1999; 80: 1828-9.
76. Greer CE, Peterson SL, Kiviat NB, Manos MM,. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol. 1991; 95: 117-24.
77. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-50.
78. Morris BJ,. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med. 2005; 43: 1171-7.
79. French D, Lorenzon L,. HPV infections: basis of neoplastic transformation and related molecular tests. Curr Pharm Des. 2013; 19: 1371-8.
80. Koskinen WJ, Chen RW, Leivo I, Makitie A, Back L, Kontio R, et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer. 2003; 107: 401-6.